Independent Auditors' Report

To the Board of Directors of Aragen Biologics Private Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the special purpose financial statements of Aragen Biologics Private Limited ("the Company"), which comprise the Balance Sheet as at 31 March 2024, and the Statement of Profit and Loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policies and other explanatory information (hereinafter referred to as "the special purpose financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid special purpose financial statements give a true and fair view in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2024, and its loss and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act, including Standard on Auditing (SA) 800, "Special Considerations — Audits of Financial Statements Prepared in Accordance with Special Purpose Frameworks". Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the special purpose financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the special purpose financial statements.

Management's and Board of Directors' Responsibilities for the Financial Statements

The Company's management and Board of Directors are responsible for the preparation of these special purpose financial statements that give a true and fair view of the state of affairs, loss (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring accuracy and completeness of the accounting records,

AGARWAL & LADDA * HYDERABAD * Chartered Accountants

relevant to the preparation and presentation of the special purpose financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the special purpose financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the special purpose financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these special purpose financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the special purpose financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the special purpose financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the special purpose financial statements, including the disclosures, and whether the special purpose financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

AGARWAL & LADDA
HYDERABAD
Chartered Accountants

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matter

These special purpose financial statements have been prepared by the management of the Company solely for the purpose of preparation the restated consolidated financial information of the Company's Holding Company, Aragen Life Sciences Limited, and do not constitute the statutory financial statements of the Company for the year ended 31 March 2024.

These special purpose financial statements have also been prepared, and this report has been issued, **for the purpose of enabling Aragen Life Sciences Limited, the Holding Company, to undertake its proposed initial public offering of equity shares** (the "Offer"). Accordingly, these special purpose financial statements and our report thereon are intended to enable the Holding Company to prepare and present its restated consolidated financial information, and to include the financial information of the Company therein, in the draft red herring prospectus, the red herring prospectus and the prospectus (collectively, the "Offer Documents") to be filed by the Holding Company with the Securities and Exchange Board of India, the stock exchanges and the Registrar of Companies in connection with the Offer, in accordance with the requirements of Section 26 of the Act read with the Companies (Prospectus and Allotment of Securities) Rules, 2014, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and the Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India.

The statutory financial statements of the Company for the financial year ended 31 March 2024 prepared for general purpose in accordance with the Companies Act, 2013, were audited by other Chartered Accountants, the statutory auditors of the Company for the year, who expressed unmodified opinions for the year ended 31 March 2024 vide their reports dated 22 May 2024.

Our report is issued solely for the purposes stated above and is accordingly restricted in its use to the Board of Directors and management of the Company. These special purpose financial statements and our report thereon may not be suitable for any other purpose, and should not be used, referred to or distributed for any other purpose or to any other person without our prior written consent.

For M/s Agarwal and Ladda
Chartered Accountants
Firm Registration Number: 012510S

AGARWAL & LADDA HYDERABAD Chartered Accountants

Deepak Ladda
Partner
Membership No.: 223832
Place: Hyderabad
UDIN: 26223832RMYKFU2243

Aragen Biologics Private Limited
Balance Sheet as at 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

Particulars	Notes	As at 31 March 2024
Assets		
Non-current assets		
Property, plant and equipment	3(a)	3,462.80
Capital work-in-progress	3(a)	103.68
Other intangible assets	4	6.77
Right-of-use assets	3A	1,042.73
Financial assets		
- Other financial assets	5	0.10
Deferred tax assets (net)	22	43.78
Non-current tax assets (net)	22	3.55
Other non-current assets	9	1,337.68
Total non-current assets		**6,001.09**
Current assets		
Inventories	6	-
Financial assets		
- Trade receivables	7	28.27
- Cash and cash equivalents	8	540.81
- Other financial assets	5	8.16
Other current assets	9	2.48
Total current assets		**579.72**
Total assets		**6,580.81**
Equity and liabilities		
Equity		
Equity share capital	10	2,000.00
Other equity	11	(200.33)
Total Equity		**1,799.67**
Liabilities		
Non-current liabilities		
Financial liabilities		
- Lease liabilities	3A	1,056.98
Provisions	12	7.14
Total non-current liabilities		**1,064.12**
Current liabilities		
Financial liabilities		
- Lease liabilities	3A	27.01
- Trade payables	13	
-Total outstanding dues of micro and small enterprises		-
-Total outstanding dues of creditors other than micro and small enterprises		29.23
- Other financial liabilities	14	3,644.47
Other current liabilities	15	10.54
Provisions	12	5.77
Total current liabilities		**3,717.02**
Total liabilities		**4,781.14**
Total equity and liabilities		**6,580.81**
Company overview & Material accounting policies	1 & 2	

The notes referred to above form an integral part of these financial statements.

As per our Report of even date attached
For M/s Agarwal and Ladda
Chartered Accountants
ICAI Firm Registration No.: 012510S

AGARWAL & LADDA HYDERABAD Chartered Accountants

Deepak Ladda
Partner
Membership No. 223832

Place: Hyderabad
Date: 28 July 2026

for and on behalf of the Board of Directors of
Aragen Biologics Private Limited
CIN: U21001TS2023PTC174243

Manmahesh Kantipudi
Director
DIN: 05241166

Keshav Gunupati Venkat Reddy
Director
DIN: 06593325

Sachin Anand Dharap
Chief Financial Officer

Ramakrishna Kasturi
Company Secretary
M.No.: F3865

Place: Hyderabad
Date: 28 JULY 2026

Place: Hyderabad
Date: 28 JULY 2026

Aragen Biologics Private Limited
Statement of Profit and Loss for the period ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

Particulars	Notes	For the year ended 31 March 2024
Revenue from operations	16	28.27
Total income		**28.27**
Expenses		
Cost of chemicals, reagents and consumables consumed	17	11.56
Employee benefits expense	18	86.72
Finance costs	19	15.30
Depreciation and amortisation expense	20	106.72
Other expenses	21	54.96
Total expenses		**275.26**
Profit/(Loss) before tax before Exceptional item		**(246.99)**
Exceptional item		-
Profit/ (Loss) before tax after Exceptional item		**(246.99)**
Tax expense		
(a) Current tax	22	
(b) Deferred tax expense/(benefit)	22	(43.78)
Total tax expense		**(43.78)**
Profit/(loss) for the period		**(203.21)**
Other comprehensive income/(loss)		
Items that will not be reclassified subsequently to profit or loss		
Remeasurement gain/(loss) on defined benefit plans		-
Income-tax effect on above		-
Total other comprehensive income/(loss), net of tax		-
Total comprehensive income for the period		**(203.21)**
Earnings per share (EPS)		
(a) Basic (In ₹)	23	(1.02)
(b) Diluted (In ₹)	23	(1.02)
Company overview & Material accounting policies	1 & 2	

The notes referred to above form an integral part of these financial statements.

As per our Report of even date attached
For M/s Agarwal and Ladda
Chartered Accountants
ICAI Firm Registration No.: 012510S

AGARWAL & LADDA HYDERABAD Chartered Accountants

Deepak Ladda
Partner
Membership No. 223832

Place: Hyderabad
Date: 28 July 2026

for and on behalf of the Board of Directors of
Aragen Biologics Private Limited
CIN: U21001TS2023PTC174243

Manmahesh Kantipudi
Director
DIN: 05241166

Place: Hyderabad
Date: 28 July 2026

Keshav Gunupati Venkat Reddy
Director
DIN: 06593325

Place: Hyderabad
Date: 28 July 2026

Sachin Anand Dharap
Chief Financial Officer

Place: Hyderabad
Date: 28 July 2026

Ramakrishna Kasturi
Company Secretary
M.No.: F3865
Place: Hyderabad
Date: 28 July 2026

Aragen Biologics Private Limited
Statement of cash flows for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

Particulars	For the year ended 31 March 2024
Cash flow from operating activities	
Profit/(Loss) before tax	**(246.99)**
Adjustments for:	
Depreciation and amortisation expense	106.72
Interest income	-
Interest expense	15.30
Employee stock compensation expense	2.88
Adjustments for working capital	
Movement in trade receivables	(28.27)
Movement in other non-current financial assets	(0.10)
Movement in other current financial assets	
Movement in other current assets	(10.64)
Movement in trade payables	29.23
Movement in other current financial liabilities	16.45
Movement in provisions	12.91
Movement in other current liabilities	10.54
Cash generated from operations	**(91.97)**
Income-tax paid(net)	(3.55)
Net cash flow generated from operating activities	**(95.52)**
Cash flows from investing activities	
Acquisition of property, plant and equipment, capital work-in-progress and intangible assets (net-off of capital advances and capital creditors)	(1,353.67)
Net cash used in investing activities	**(1,353.67)**
Cash flow from financing activities	
Proceeds from issue of equity shares	2,000.00
Proceeds from issue of Preference shares	-
Proceeds from long-term borrowings	-
Repayment of Long term borrowings	-
Principal payment of lease liebilities(including interest)	(10.00)
Proceeds from short-term borrowings, net	-
Finance costs paid	-
Net cash flow (used in)/generated from financing activities	**1,990.00**
Net increase/(decrease) in cash and cash equivalents	**540.81**
Cash and cash equivalents at the beginning of the year	-
Cash and cash equivalents at the end of the year	**540.81**

Cash and cash equivalents comprise

Particulars	As at 31 March 2024
Balances with banks	
On current accounts	540.81
Fixed deposits with maturity of less than 3 months	-
Cash on hand	-
Total cash and cash equivalents at end of the year	**540.81**

Refer note 14 for Reconcilaition of Liabilities from Financial Activities

The notes referred to above form an integral part of the financial statements

As per our Report of even date attached
For M/s Agarwal and Ladda
Chartered Accountants
ICAI Firm Registration No.: 012510S

AGARWAL & LADDA HYDERABAD Chartered Accountants

Deepak Ladda
Partner
Membership No. 223832

Place: Hyderabad
Date: 28 July 2026

for and on behalf of the Board of Directors of
Aragen Biologics Private Limited
CIN: U21001TS2023PTC174243

Manmahesh Kantipudi
Director
DIN: 05241166

Place: Hyderabad
Date: 28 July 2026

Keshav Gunupati Venkat Reddy
Director
DIN: 06593325

Place: Hyderabad
Date: 28 July 2026

Sachin Anand Dharap
Chief Financial Officer

Place: Hyderabad
Date: 28 July 2026

Ramakrishna Kasturi
Company Secretary
M.No.: F3865
Place: Hyderabad
Date: 28 July 2026

Aragen Biologics Private Limited
Statement of Changes in Equity for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

(a) Equity and Preference share capital

Particulars	Number	Amount
Equity shares of ₹10 each issued, subscribed and fully paid		
Balance as at 01 April 2023	-	-
Add: Shares issued during the year	2,00,00,000	2,000.00
As at 31 March 2024	**2,00,00,000**	**2,000.00**

(b) Other equity

Particulars	Reserves and Surplus		Total other equity
	Retained earnings	Capital Contribution from parent company	
Balance as at 31 March 2023	-	-	-
Loss for the year	(203.21)	-	(203.21)
Other comprehensive income	-	-	-
Issue of stock options by the Holding Company	-	2.88	2.88
Balance as at 31 March 2024	**(203.21)**	**2.88**	**(200.33)**

The notes referred to above form an integral part of these financial statements.

As per our Report on financial statements of even date attached

For M/s Agarwal and Ladda
Chartered Accountants
ICAI Firm Registration No.: 012510S

AGARWAL & LADDA * HYDERABAD * Chartered Accountants

Deepak Ladda
Partner
Membership No. 223832

Place: Hyderabad
Date: 28 July 2026

for and on behalf of the Board of Directors of
Aragen Biologics Private Limited
CIN: U21001TS2023PTC174243

Manmahesh Kantipudi
Director
DIN: 05241166

Place: Hyderabad
Date: 28 July 2026

Keshav Gunupati Venkat Reddy
Director
DIN: 06593325

Place: Hyderabad
Date: 28 July 2026

Sachin Anand Dharap
Chief Financial Officer

Place: Hyderabad
Date: 28 July 2026

Ramakrishna Kasturi
Company Secretary
M.No.: F3865

Place: Hyderabad
Date: 28 July 2026

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

3 Property, plant and equipment & Capital work-in-progress

(a) Property, plant and equipment

Particulars	Leasehold Improvements	Plant & Machinery	Laboratory equipment	Furniture and fixtures	Office equipment	Computer and related equipment	Total
A.Cost or Deemed Cost (Gross Carrying amount)							
As at 31 March 2023							
Additions during the year	183.13	63.52	2,051.52	6.88	1,217.55	10.67	3,533.27
Adjustments/Disposals							
As at 31 March 2024	**183.13**	**63.52**	**2,051.52**	**6.88**	**1,217.55**	**10.67**	**3,533.27**
Accumulated depreciation							
As at 31 March 2023							
Charge for the year	1.00	0.70	42.10	0.10	25.99	0.58	70.47
Adjustments or disposals							-
As at 31 March 2024	**1.00**	**0.70**	**42.10**	**0.10**	**25.99**	**0.58**	**70.47**
Net block as at							
As at 31 March 2024	**182.13**	**62.82**	**2,009.42**	**6.78**	**1,191.56**	**10.09**	**3,462.80**

Notes:
(i) The Company has not revalued its property, plant and equipment during the current and previous financial year.
(ii) Refer note 25 for disclosure of contractual commitments for the acquisition of property, plant and equipment.

Capital work-in-progress:
Capital work-in-progress (CWIP) comprises expenditure for the building, plant and machinery, laboratory and electrical equipment in the course of construction. The balance of CWIP as at 31 March 2024: ₹103.68.

Particulars	As at 31 March 2024
Balance at the beginning of the year	-
Less: Capitalised during the year	-
Add: Additions to CWIP during the year	103.68
Balance at the end of the year	**103.68**

Ageing for capital work-in-progress as at March 31, 2024 is as follows:

	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	103.68	-	-	-	103.68
Projects temporarily suspended	-	-	-	-	-
Total	**103.68**	-	-	-	**103.68**

Details of expenditure capitalised during the year

Particulars	As at 31 March 2024
Balance at the beginning of the year	-
Add:Expenditure incurred during the year	-
- Interest expense	-
- Salaries and contract services	61.98
- Clearing Charges	-
- Power and Fuel	-
-Others	41.70
Less: Capitalized to prpoperty, plant and equipment during the year	-
Balance at the end of the year	**103.68**

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

3A Right-of-use assets ("ROU Assets")

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate.

The Company lease comprises of buildings. The lease pertains to building taken for total period of 5 years. The weighted average incremental borrowing rate of 8.50% p.a. has been applied to lease payments recognized in the balance sheet at the date of initial application.

The Company also has certain leases with lease terms of 12 months or less and leases with low value. The Company has elected to apply the practical expedient permitted under Ind AS 116 "Leases" for short-term leases and low-value leases. Short-term leases are those with a lease term of 12 months or less. The lease payments associated with these leases are recognized as an expense in the statement of profit and loss (refer note 22).

Following are the changes in the carrying values of right of use assets for the period ended 31 March 2024

Particulars	Buildings	Total
A.Gross carrying amount		
As at 01 April 2023	-	-
Additions during the year	1,078.69	1,078.69
Less: Adjustments/Disposals	-	-
As at 31 March 2024	**1,078.69**	**1,078.69**
Accumulated depreciation		
As at 01 April 2023		
Charge for the year	35.96	35.96
Less: Adjustments/ Disposals		
Up to 31 March 2024	**35.96**	**35.96**
Net Carrying Amount as at 31 March 2024	**1,042.73**	**1,042.73**

(i) The company has not revalued any Right-of-use assets after initial recognition, during the current year and previous financial year

(ii) The aggregate Depreciation expense on Right-of-use assets is included under depreciation and amortization expense in the statement of Profit and Loss.

The following is the movement in lease liabilities during the year ended 31 March 2024

Particulars	As at 31 March 2024
Balance at the beginning of the year	**1,078.68**
Add:Additions	-
Less: Derecognized during the year	-
Add:Finance cost accrued during the year	15.30
Less:Payment of lease liabilities(including interest thereon)	(10.00)
'Balance at the end of the year	**1,083.98**

The following is the break-up of current and non-current lease liabilities

Particulars	As at 31 March 2024
Current lease liabilities	27.01
Non-current lease liabilities	1,056.97
Total	**1083.98**

The details of the contractual maturities of lease liabilities as at respective year ended on an undiscounted basis are as follows:

Particulars	As at 31 March 2024
Less than one year	27.01
One to five years	1,056.97
More than five years	
Total	**1083.98**

3A Right-of-use assets ("ROU Assets") and Lease liabilities (continued)

The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

Amounts recognised in the statement of profit and loss

Particulars	For the year ended 31 March 2024
Interest on lease liabilities	15.30
Depreciation expense for the year	35.96
Short-term leases (refer note 25)	
Total	**51.26**

Impact on Statement of Cash Flows

Particulars	For the year ended 31 March 2024
Payment of lease liabilities(including interest)	10.00
Net Cash flows used in financing activities	**10.00**

HYDERABAD
Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

4 **Other intangible assets**

Particulars	Computer Software	Total
As at 31 March 2023	-	
Additions during the year	7.05	
Less: Adjustments/disposals during the year	-	
As at 31 March 2024	**7.05**	
Accumulated amortization		
As at 31 March 2023	-	
Charge for the year	0.29	
As at 31 March 2024	0.29	
Net Carrying Amount	6.77	

Notes:
(i) The Company has not revalued its Intangible assets during the current and previous financial year.
(ii) There are no Intangible assets under development as at 31 March 2024.

5 **Other financial assets**
(Unsecured, considered good unless stated otherwise)

	Particulars	As at 31 March 2024
A	**Non-current**	
	Security deposits	0.10
		0.10
B	**Current**	
	Other assets (Receivable from holding company) (Refer note 35)	-
		8.16
	Total other financial assets	**8.26**

Notes: Information about the company's exposure to credit risk, foreign currency risk, interest rate risk and fair value measurement is included in note 29.

6 **Inventories**

	As at 31 March 2024
Valued at the lower of cost and net realisable value	
Chemicals and consumables	-
Stores and spares	-
	-

7 **Trade receivables**

Particulars	As at 31 March 2024
Unsecured considered good	
- related parties (refer note 35)	16.17
- other parties	12.10
	28.27
Unsecured considered doubtful	
- related parties (refer note 35)	-
- other parties	-
	-
Less: Allowance for expected credit loss	-
Total trade receivables	**28.27**
Trade receivables considered good - secured	-
Trade receivables considered good - unsecured	28.27
Trade receivables which have significant credit risk	-
Trade receivables - credit impaired	-
Total	**28.27**
Provision for loss allowance	-
Total trade receivables	**28.27**

Particulars	31 March 2024
Trade receivables considered good - secured	-
Trade receivables considered good - unsecured	28.27
Trade receivables which have significant credit risk	-
Trade receivables - credit impaired	-
Total	**28.27**
Loss allowance	-
Total trade receivables	**28.27**

(i) No trade or other receivables are due from directors or other officers of the Company either severally or jointly with any other person. Trade receivables from related parties represent dues from private companies in which a director is director or a member.

(ii) Trade receivables are non-interest bearing and are generally on terms of 30 to 90 days.

Trade Receivables ageing schedule as at 31 March 2024:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months -1 year	1-2years	2-3years	More than 3 years	Total
Undisputed trade receivables							
- considered good	-	28.27	-	-	-	-	28.27
- significant increase in credit risk	-	-	-	-	-	-	-
- credit impaired	-	-	-	-	-	-	-
Disputed trade receivables							
- considered good	-	-	-	-	-	-	-
- significant increase in credit risk	-	-	-	-	-	-	-
- credit impaired	-	-	-	-	-	-	-
Total	-	**28.27**	-	-	-	-	**28.27**
Expected Loss Rate	0%	0%	0%	0%	0%	0%	
Loss Allowance provision	-	-	-	-	-	-	-

AGARWAL & LADDA HYDERABAD Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

8 Cash and bank balances

Particulars	As at 31 March 2024
Cash and cash equivalents	
Balances with banks	
-In current accounts	540.81
-Fixed deposits (Maturity period less than 3 months)	-
Cash on hand	-
	540.81

9 Other assets
(Unsecured, considered good unless stated otherwise)

Particulars	As at 31 March 2024
Unsecured, considered good	
Non-current	
Capital advances	1,337.68
Balances with government authorities	
	1,337.68
Current	
Advance for expenses	-
Balances with government authorities	2.48
Prepaid expenses	-
Employee advances	-
	2.48

Notes:
(i) No loss allowance as at 31 March 2024
(ii) There are no advances due from directors or other officer of the Company or any of them either severally or jointly with any other persons nor any advance are due from firms or private limited companies respectively in which any director is a partner or a director or a member except as disclosed above.

10 Equity share capital

Particulars	31 March 2024	
	Number	Amount
Authorized		
Equity shares of ₹10 each	30,000,000	3,000.00
Preference shares of ₹1,00,000 each	21,500	21,500.0
Increase during the year		
	30,021,500.00	**24,500.00**
Issued, subscribed and fully paid-up		
Equity shares of ₹10 each as on 31.03.2025	20,000,000	2,000
Add: Shares issued during the year		
	20,000,000	**2,000**

(a) Reconciliation of equity shares outstanding at the beginning and end of the reporting year

Particulars	31 March 2024	
	Number	Amount
Balance at the beginning of the year	-	-
Bonus shares issued during the year		
Shares issued during the year	20,000,000	2,000
Balance at the end of the year	**20,000,000.00**	**2,000.00**

(b) Details of shareholders holding more than 5% shares in the Company

Particulars	31 March 2024	
	Number of shares	% of holding
Equity shares of ₹10 each fully paid		
Aragen Life Sciences Limited*	20,000,000	100.00%
Goldman Sachs Asia Strategic Pte. Ltd		

**(Including 1 share in the name of nominee Keshav Gunupati Venkat Reddy)*

(c) Shareholdings of Promoters

Particulars	31 March 2024	
	No. of Shares	% of total shares
Aragen Life Sciences Limited	19,999,999	99.99%
Keshav Gunupati Venkat Reddy (As a nominee of Aragen Life Sciences limited)	1	0.00%

(d) No equity shares bought back during the year and since the date of incorporation.
(e) There are no shares issued pursuant to contract without payment being received in cash during the year and since the date of incorporation.
(f) No shares have been allotted as fully paid up by way of bonus shares during the year and since the date of incorporation.

AGARWAL & LADDA HYDERABAD Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

11 Other equity

Particulars	As at 31 March 2024
Retained earnings	
Balance at the beginning of the year	-
Add: Net profit/(loss) for the year	(203.21)
Add/(Less): Other comprehensive income net of tax	-
Balance at the end of the year	**(203.21)**
Capital contribution from parent company	
Balance at the beginning of the year	-
Add: Contribution towards employees of Subsidiary	2.88
Balance at the end of the year	**2.88**
Total other equity	**(200.33)**

Nature and purpose of reserves
Retained earnings:
Retained earnings represents the Company's undistributed earnings after taxes.
Capital contribution by Holding company:
The holding company has granted equity settled share based plans for the employees of the Company and subsidiary Company. The fair value of this share option has been recognised as Capital contribution from holding company.

12 Provisions

Particulars	As at 31 March 2024
Non-current	
Provision for employee benefits	
- Provision for gratuity (refer note 22)	7.14
	7.14
Current	
Provision for employee benefits	
- Provision for gratuity (refer note 22)	-
- Provision for compensated absences	5.77
	5.77

13 Trade payables

Particulars	As at 31 March 2024
Current	
Total outstanding dues of micro enterprises and small enterprises (herein referred to as 'MSME' (refer note below)	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	-
- related parties (refer note 35)	29.23
- others	-
	29.23

(a) Trade payables are non-interest bearing and are normally settled on 0-90 day terms.
(b) For terms and conditions with related parties, refer to note 35
(c) Information about the companies exposure to foreign currency risks, liquidity risk and fair value measurement is included in note 29

Trade payables ageing schedule as at 31 March 2024:

Particulars	Outstanding for following periods from due date of payment					
	Not Due- Trade Payables	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
(i) MSME	-	-	-	-	-	-
(ii) Others	-	28.23	-	-	-	28.23
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
(v) Accrued for expenses	-	-	-	-	-	-
	-	**28.23**	**-**	**-**	**-**	**28.23**

14 Other financial liabilities

Particulars	As at 31 March 2024
Current	
At amortised cost	
Creditors for capital expenditure	3,628.02
Employee Benefits Payable	-
Payables to related party (Refer note 35)	16.45
Interest accrued but not due on borrowings.	-
	3,644.47

(a) Information about company's exposure to liquidity and currency risk is included in note 29.

15 Other current liabilities

Particulars	As at 31 March 2024
Statutory liabilities	10.54
	10.54

AGARWAL & LADDA ★ HYDERABAD ★ Chartered Accountants

(All amounts in ₹ lakhs, except share data, unless otherwise stated)

16 Revenue from operations

Particulars	For the year ended 31 March 2024
Sale of goods:	
- Pharmaceutical Products Sales	28.27
	28.27

Revenues from Contracts with Customers establishes a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied.

In relation to information about the Company's performance obligations in contracts with customers refer note 2(a). The aggregate value of transaction price allocated to unsatisfied (or partially satisfied) performance obligations is Nil (31 March 2024: Nil) out of which 100% is expected to be recognised as revenue in the next year. No consideration from contracts with customers is excluded from the amount mentioned above.

(a) Information about products and services

Disaggregation of revenue from contract research and manufacturing activities into over time and at a point in time:

Particulars	Timing of recognition (Over the period / Point in time)	For the year ended 31 March 2024
Sale of goods	Point in time	28.27
Sale of services	Over the period	-
Total		**28.27**

(b) Contract balances:

Particulars	31 March 2024
Trade receivables	28.27
Contract Assets	-
Contract liabilities	-

(i) The contract assets primarily relate to the Company's rights to consideration for work completed but not billed as at the reporting date as the billing is conditional upon completion of milestone. The contract assets are transferred to receivables when the rights become unconditional.

(ii) The contract liabilities primarily relate to unearned revenue. This will be recognised as revenue when the performance obligations is satisfied, which is expected to occur over the next 12 months.

(c) **Reconciliation of revenue with contract price**

	For the year ended 31 March 2024
Revenue as per contracted price	28.27
Adjustments for:	
Less : Discounts	-
Less : Sales returns	-
Revenue from operations	**28.27**

17 Cost of materials, chemicals, reagents and consumables consumed

	For the period ended 31 March 2024
Inventory at the beginning of the year	-
Add: Purchases of raw materials	11.56
	11.56
Less: Inventory at the end of the year	-
	11.56

AGARWAL & LADDA HYDERABAD Chartered Accountants

(All amounts in ₹ lakhs, except share data, unless otherwise stated)

18 Employee benefits expense

Particulars	For the year ended 31 March 2024
Salaries and wages	76.76
Equity-settled share-based payment (refer note 12)	2.88
Contribution to provident and other funds (refer note a)	1.77
Gratuity and compensated absences (refer note b)	4.74
Staff welfare expenses	0.57
	86.72

a. Defined contribution plan

During the year ended 31 March 2025, the Company has contributed ₹1.77 to provident fund, 31 March 2024: Nil towards employee state insurance fund and ₹ Nil (31 March 2024: ₹Nil towards National Pension Scheme.

b. Defined benefit plan

The Company has a defined benefit plan, viz. gratuity for its employees. Under the gratuity plan, every employee who has completed at least five years of service gets a gratuity on departure @ 15 days of last drawn salary for each completed year of

The gratuity plan is governed by the Payment of Gratuity Act, 1972. Under the act, employee who has completed five years of service is entitled to specific benefit. The level of benefits provided depends on the member's length of service and salary at

Interest Rate risk: The plan exposes the Company to the risk of fall in interest rates. A fall in interest rates will result in an increase in the ultimate cost of providing the above benefit and will thus result in an increase in the value of the liability.

Liquidity Risk: This is the risk that the Company is not able to meet the short-term gratuity payouts. This may arise due to non availability of enough cash / cash equivalent to meet the liabilities or holding of illiquid assets not being sold in time.

Investment Risk: The probability or likelihood of occurrence of losses relative to the expected return on any particular investme
The Company has determined that, in accordance with the terms and conditions of the gratuity plan, and in accordance with statutory requirements (including minimum funding requirements) of the plan of the relevant jurisdiction, the present value of refund or reduction in future contributions is not lower than the balance of the total fair value of the plan assets less the total present value of obligations. As such, no decrease in the defined benefit asset is necessary at 31 March 2024: no decrease in defined benefit asset). Project unit credit method has been used for valuation.

Introduction of New Wage Code 2020

On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and accounted for the incremental impact of these changes on the basis of its internal assessment and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Accordingly, the potential obligation of the Company towards its employees have been duly recognized in the statement of profit and loss.

19 Finance costs

Particulars	For the year ended 31 March 2024
Interest expense on financial liabilities measured at amortised cost	-
Interest cost on liability component of preference shares	-
Interest expense on lease liabilities	15.30
	15.30

20 Depreciation and Amortisation

Particulars	For the year ended 31 March 2024
Depreciation on property, plant and eqiupment. (Note 3)	70.47
Amortisation on right of use Assets (Note 3A)	35.96
Amortisation of Intangible assets(Note 4)	0.29
	106.72

21 Other expenses

Particulars	For the year ended 31 March 2024
a) Direct expenses:	
Job work charges	-
Other direct expenses	-

AGARWAL & LADDA * HYDERABAD * Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

b) Indirect expenses:

Power and fuel	26.14
Rent	1.24
Repairs and maintenance	
- Buildings	0.40
- Machinery	0.45
- Others	-
Insurance	-
Bank charges	1.26
Rates and taxes	0.25
Water charges	1.51
Communication expenses	0.02
Office maintenance expenses	9.47
Travelling and conveyance	1.75
Consultancy and professional charges	0.33
Printing and stationery	1.11
Other expenses	6.03
	49.96

(c) Payments to the auditor

	For the year ended 31 March 2025
-As Auditor	
- statutory audit fee	5.00
	5.00

22 Income Taxes

A. Tax expense in the statement of profit and loss

Particulars	For the year ended 31 March 2024
Current tax	-
Current tax relating to prior years	-
Deferred tax expense/(benefit)	(43.78)
Tax expense reported in the statement of profit or loss	**(43.78)**

Tax expense charged to OCI

Particulars	For the year ended 31 March 2024
Tax related to items in OCI during the year:	
Tax impact due to remeasurements of defined benefit plans	-
Tax expense reported in OCI	-

Reconciliation of effective tax rate

Particulars	For the year ended 31 March 2024
Tax expense for the year	(43.78)
Profit/ (loss) before tax for the year ended as per statement of profit and loss	(246.99)
Tax at statutory income tax rate 17.16%	(42.38)
Tax effects of amounts which are not deductible / (taxable) in calculating taxable income	
Non-deductible expenses for tax purposes	(1.40)
Tax expense for the year	**(43.78)**

B Non-current tax assets, net

Particulars	As at 31 March 2024
Tax Assets(net of provision for tax: Nill)	3.55
	3.55

AGARWAL & LADDA
HYDERABAD
Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

C Deferred tax assets, net

Particulars	As at 31 March 2024
The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities are	
Deferred income tax liabilities	
Property, plant and equipment	31.62
	31.62
Deferred income tax assets	
Accrued compensation to employees	2.21
Statutory Bonus	0.08
Carryforward business loss and Unabsorbed depreciation	
Leases	7.08
Others	66.03
	75.40
Total Deferred tax assets, net	**43.78**

Deferred tax
The Company has recognised deferred tax assets only to the extent of deferred tax liabilities in the absence of convincing evidence of future taxable profits. It is expected that any reversals of the deferred tax liability would be offset against the reversal of the deferred tax assets.

D. Reconciliation of deferred tax assets/ (liabilities) (net):

Particulars	As at 31 March 2024
Balance at the beginning of the year	
Tax income/(expense) during the year recognised in profit or loss	43.78
Tax income/(expense) during the year recognised in OCI	
Balance at the end of the year	**43.78**

Movement in deferred tax balances as at 31 March 2024

Particulars	Opening balance	Recognised in statement of profit and loss
Deferred tax liabilities:		
Property, plant and equipment	-	31.62
Deferred tax assets:	-	**31.62**
Accrued compensation to employees	-	2.21
Carryforward business loss and Unabsorbed depreciation	-	66.03
Leases	-	7.08
Others	-	0.08
	-	**75.40**
Deferred tax assets (net)	-	**43.78**

23 Earnings per Equity share (EPES)
Basic EPS amount are calculated by dividing the profit for the year attributable to equity holders of the Company by the weighted average number of equity shares outstanding during the year.
The following reflects the income and share data used in the basic EPS computations:

Particulars	For the year ended 31 March 2024
Profit attributable to equity holders	(203.21)
Weighted average number of equity shares in calculating basic EPS	20,000,000
Nominal value per equity share	₹10

Earnings per Equity share (EPES)	31 March 2024
Basic	(1.02)
Diluted	(1.02)

* In view of losses incurred during the current year and previous year, the impact of dilutive instruments has not been considered as these would be anti-dilutive.

AGARWAL & LADDA HYDERABAD * Chartered Accountants *

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

24 Fair value measurements
(i) Breakup of financial assets and financial liabilities carried at amortized cost

	As at 31 March 2024
Financial assets	
- Loans	-
- Other financial assets	8.26
- Trade receivables	28.27
- Cash and cash equivalents	540.81
Total	**577.34**
Financial liabilities	
- Non-current Borrowings	-
- Lease Liability	1,083.99
- Current borrowings	-
- Trade payables	29.23
- Other financial liabilities	3,644.47
Total	**4,757.69**

Note: The Company has not disclosed fair values of financial assets and liabilities such as trade receivables, cash and cash equivalents, other financial assets, borrowings, lease liabilities, trade payables and other financial liabilities since their carrying amounts are reasonable approximates of fair values.

(ii) The Company has not disclosed investment above, as these investments are carried at cost.

25 Financial risk management objectives and policies

(i) The Company's principal financial liabilities, comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include loans, trade and other receivables, and cash and bank balances that derive directly from its operations.
(ii) The Company is exposed to market risk, credit risk and liquidity risk. The Company's senior management oversees the management of these risks. The senior management provides assurance to the Company's Board that the Company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives. The Board of Directors monitors the compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

(iii) The carrying amounts of trade receivables, trade payables and cash and cash equivalents are considered to be the same as their fair values, due to their short-term nature. Difference between carrying amounts and fair values of bank deposits, other financial assets, other financial liabilities and borrowings subsequently measured at amortised cost is not significant in each of the years presented as these instruments are linked to Market interest rates. For all other amortised cost instruments, carrying value represents the best estimate of fair value. For the financial assets measured at fair values, the carrying amounts are equal to the fair values.

(iv) The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods

(i) Interest rate risk
Interest rate risk is the risk that the fair value or future cash flows of the Company's and the Company financial instruments will fluctuate because of

(ii) Credit risk
Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments. The carrying amount of the Financial assets represents the

(iii) Market Risk
Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates will affect the Company's income or value of its holdings of financial instrumènts. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing return. Our Board of Directors are responsible for overseeing our risk assessment and management policies. Our major market risks of foreign exchange and interest rate risk are managed by our finance department, which evaluates and exercises independent control over the entire process of market risk management.

(iv) Currency Risk
Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rate. The company's presentation currency in Indian Rupees. The Company's exposure to foreign currency arises in part when the company holds financial assets and liabilities denominated in currency different from the functional currency of the entity

(i) Equity risk
As the Company is not listed in any stock exchange, the equity risk is not applicable to the Company.

(v) Trade receivables
Customer credit risk is managed by each business unit subject to the Company's established policy, procedures and control relating to customer credit risk management. Outstanding customer receivables are regularly monitored. The Company has a policy of providing for all aged receivables basis the Expected Credit Loss method and specific provision on a case to case basis.
Loans given to Subsidiary:
The loans from subsidiary is payable on demand and there is no significant credit risk involved as it is a wholly owned subsidiary

(vi) Financial instruments and cash deposits
Credit risk from balances with banks is managed by the Company's finance team in accordance with the Company's policy. Investments of surplus funds are made only with approved and reputed banks and within credit limits assigned to each bank. The amounts invested and details of relevant banks are reviewed by the Company's Board of directors on annual basis.

HYDERABAD
Chartered Accountants

(All amounts in ₹ lakhs, except share data, unless otherwise stated)

Financial risk management objectives and policies (continued)

(vii) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company has an appropriate liquidity risk management framework for the management of short, medium and long-term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate cash reserves, banking facilities and reserve borrowing facilities by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The Company's treasury department is responsible for managing the short-term and long term liquidity requirements of the Company. Short term liquidity situation is reviewed daily by treasury. Long term liquidity position is reviewed on a regular basis by the Board of Directors and appropriate decisions are taken according to the situation.

Typically the Company ensures that it has sufficient cash on demand to meet expected operational expenses for a period of 60 days, including the
The carrying value of the Company's financial liabilities are disclosed in note 3A and note 14, 16 and 17 of the financial statements.
The table below summarises the maturity profile of the Company's financial liabilities based on contractual undiscounted payments.

Particulars	**As at** **As at 31 March 2024**
On demand	
- Borrowings	-
Less than 1 year	
- Borrowings	-
- Other financial liabilities	3,644.47
- Trade payables	29.23
- Lease liabilities	27.01
1 to 2 years	
- Borrowings	-
- Lease liabilities	222.32
2 to 5 years	
- Borrowings	-
- Lease liabilities	834.66
> 5 years	
- Borrowings	-
- Lease liabilities	-

'Note: The above amounts excludes the future interest payment under the contractual obligations and impact of compulsory convertible preference shares.

26 Capital management

For the purpose of the Company's capital management, capital includes issued equity capital and other equity reserves attributable to the equity holders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.
The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, issue bonus shares to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital. The Company's policy is to keep the gearing ratio in an optimal structure which balances growth and shareholder value. The Company includes within net debt, interest bearing

	As at **at 31 March 2024**
Borrowings	-
Less: Cash and bank balances (Note 10)	(540.81)
Net debt	**4,216.87**
Total equity	1,799.67
Total equity	**1,799.67**
Capital and net debt	**6,016.54**
Gearing ratio	**2.34**

* Includes Fixed deposits maturing after 12 months from the balance sheet date.
In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no material breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

AGARWAL & LADDA
HYDERABAD
Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

27 Ratio Analysis

a) Current Ratio = Current Assets divided by Current Liabilities

	31 March 2024
Current Assets	579.72
Current Liabilities	3,717.02
Ratio	**0.16**
% variance from previous year	

Reason for variance more than 25%
This is on account of increase in working capital loan and preference

b) Debt Equity ratio = Total debt divided by Total Equity where total debt refers to sum of current & non current borrowings

	31 March 2025
Total debt	-
Total Equity	1,799.67
Ratio	-
% variance from previous year	

Reason for variance more than 25%
This is on account of issue of Non Convertible Preference shares and

c) Debt Service Coverage Ratio = Earnings available for debt service divided by interest, lease payments and principal

	31 March 2024
Net Profit/ (loss) after tax	(203.21)
Add: Non cash operating expenses and finance cost	
Depreciation and amortization expense	106.72
Finance cost	15.30
Earnings available for debt service	**(81.19)**
Interest Payments	-
Current lease liabilities	27.01
Current maturities of long term borrowings	-
Total Interest and principal repayments	**27.01**
Ratio	**(3.01)**
% variance from previous year	

Reason for variance more than 25%
This is on account of increase in depreciation and amortization

d) Return on Equity Ratio / Return on Investment Ratio = Net profit after taxes divided by average total equity

	31 March 2024
Net profit after taxes	(203.21)
Earning available to equity shareholders	**(203.21)**
Average Total Equity	899.84
Ratio	**(0.23)**
% variance from previous year	**0.00%**

Reason for variance more than 25%
Variance is on account of increase in loss during the year

(All amounts in ₹ lakhs, except share data, unless otherwise stated)

e) Inventory Turnover Ratio = Cost of goods sold divided by

	31 March 2024
Cost of Goods Sold and Consumption of chemicals and spares	11.56
Average Inventory	-
Ratio	-
% variance from previous year	

Reason for variance more than 25%: Not applicable

f) Trade Receivables turnover ratio = Net Credit Sales divided by

	31 March 2024
Net Credit Sales	28.27
Average Trade Receivables	14.14
Ratio	**2.00**
% variance from previous year	

Reason for variance more than 25%
Increase in trade receivable on account of increase in sales during the

g) Trade payables turnover ratio = Net Credit Purchases divided

	31 March 2024
Net Credit Purchases	11.56
Trade Payables excluding accrual for expenses	29.23
Ratio	**0.40**
% variance from previous year	

Reason for variance more than 25%
This is on account of increase in material procurement during the year

28 Ratio Analysis (Continued)

h) Net capital Turnover Ratio = Net Sales divided by Working Capital where Working Capital= Current Assets - Current Liabilities

	31 March 2024
Net sales	28.27
Working Capital	(3,137.30)
Ratio	**(0.01)**
% variance from previous year	

Reason for variance more than 25%
Variance is on account of increase in sales and change in working capital during the year

AGARWAL & LADDA * HYDERABAD * Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

i) Net profit ratio = Net profit after taxes divided by Net Sales

	31 March 2024
Net profit/(loss) after taxes	(203.21)
Net Sales	28.27
Ratio	**(7.19)**
% variance from previous year	
Reason for variance more than 25%	
This is on account of increased sales during the year	

j) Return on Capital employed (pre cash)=Earnings Before Interest and Taxes (EBIT) divided by Capital Employed (pre cash)

	31 March 2024
Profit/ (loss) before tax (A)	(246.99)
Finance Costs (B)	15.30
Other Income (C)	-
EBIT (D) = (A)+(B)-(C)	**(231.69)**
Capital Employed (Pre Cash) (J)=(E)-(F)-(G)-(H)-(I)	**2,322.98**
Total Assets (E)	6,580.81
Current Liabilities (F)	3,717.02
Current Investments (G)	
Cash and Cash equivalents (H)	540.81
Bank balances other than cash and cash equivalents (I)	
Ratio (D)/(J)	**(0.10)**
% variance from previous year	
Reason for variance more than 25%	
Variances majorly on account of issue of convertible preference shares and dividens payable on those shares during the year	

k) Return on Investment = Income generated from investments/

	31 March 2024
Interest income on deposits	-
Interest income on ICD	-
Total	-
Average Investment in Preference shares	
Average Bank Deposits	-
Average Inter company Deposit	-
	-
Ratio (D)/(J)	-
% variance from previous year	**0**
Reason for variance more than 25%	
This is on account of increase in Interest on ICD and bank deposits	

AGARWAL & LADDA * HYDERABAD * Chartered Accountants

(All amounts in ₹ lakhs, except share data, unless otherwise stated)

29 Commitments

Particulars	As at 31 March 2024
Estimated amount of contracts amounting to be executed on capital account and not provided for (net of advances)	6,378.61

30 Contingent liabilities

The Company does not have any contingent liabilities as at 31 March 2024

31 Segment reporting

Operating segments

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components, and for which discrete financial information is available. All operating segments results are reviewed regularly by the Company Board of Directors (referred to as 'Chief Operating Decision Maker') to make decisions about resources to be allocated to the segments and assess their performance.

The Chief Operating Decision Maker ("CODM") evaluates the Company's performance and allocates resources based on an analysis of various performance indicators by industry classes. Based on Company business model, providing contract research, development and manufacturing services has been considered as the only reportable business segment and hence no separate financial disclosures are provided in respect of its single business segment.

Geographical information

The geographical information analyses the Company's revenues and non-current assets by the Company's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographic location of the customers and segment assets which have been based on the geographical location of the assets.

Segment revenue

	For the year ended 31 March 2024
Revenues from Contract research and sale of goods	
North America	28.27
Europe	-
India	-
Others	-
Total Revenue from operations	**28.27**

Geographical revenue is allocated based on the location of the customers.

Non-current operating assets

	As at 31 March 2024
India	5,953.79
Out of India	-
Total non-current operating assets	5953.79

*Non-current operating assets includes all the items except financial assets and tax related assets.

Information about major customers

The Company derives revenues from the following customers which amount to 10 per cent or more of the entity's

Particulars	For the year ended 31 March 2024
Customer - A	28.27
Customer - B	-
Customer - C	-
	28.27

AGARWAL & LADDA HYDERABAD Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

32 Related party disclosures

(a) Name of related parties and nature of relationship

Names of the related parties		Nature of Relationship
Aragen Life Sciences Limited		Holding Company
Aragen Bioscience Inc		Wholly Owned Subsidiary
Aragen Lifesciences B.V. (formerly known as GVK Biosciences B.V.)		Fellow Subsidiary
Aragen Biosafety Solutions Private Limited (formerly knows as Intox Private Limited)		Fellow Subsidiary
Aragen Foundation		Fellow Subsidiary
Manmahesh Kantipudi	Director	Key management personnel (KMP)
Keshav Gunupati Venkat Reddy	Director	Key management personnel (KMP)
Sachin Anand Dharap	Chief Financial Officer	Key management personnel (KMP)
Ramakrishna Kasturi	Company Secretary	Key management personnel (KMP)
Vikas Katial	Manager	Key management personnel (KMP)
Equal Identity Private Limited		Enterprises owned or significantly influenced by individuals who have control / significant influence over the Company.

33 Related party disclosures (continued)

(a) Transactions with related parties (continued)

	For the year ended Saturday, January 0, 1900
Transactions with Holding company - Aragen Life sciences Limited.	
Reimbursement of expenses receivable	8.16
Reimbursement of expenses (Rent)	(10.00)
Reimbursement of expenses	(73.34)
Purchases of fixed assets	(2,991.53)
Transactions with wholly owned subsidiary - Aragen Bioscience, Inc.	
Pharmaceutical Products Sales	16.17

Transfer pricing

The Company has established a comprehensive system of maintenance of information and documents as required by the transfer pricing legislation under Sections 92-92F of the Income-tax Act, 1961. Since the law requires existence of such information and documentation to be contemporaneous in nature, the Company is in the process of updating the documentation for the domestic and international transactions entered into with the associated enterprises during the financial year and expects such records to be in existence before the regulatory timelines, as required by law. The Management is of the opinion that its domestic and international transactions are at arm's length so that the aforesaid legislation will not have any impact on the financial statements, particularly on the amount of tax expenses and that of provision for taxation.

(iii) Refer notes 12(h), 14(ii) and 14(v) for details of stock option granted, terms of demand loan and CCPS

(iv) The Company has received an unconditional letter of support from the Holding Company committing to provide necessary operational and financial support for a period of 15 months from the date of adoption of the financial statements.

AGARWAL & LADDA
HYDERABAD
Chartered Accountants

Aragen Biologics Private Limited
Notes to the financial statements for the year ended 31 March 2024
(All amounts in ₹ lakhs, except share data, unless otherwise stated)

34 Additional regulatory information

(i) **Charge registration and satisfaction:**
The Company does not have any charges which are yet to be registered with ROC beyond the statutory period. The Company does not have any satisfaction of charges which are yet to be registered with the ROC beyond the statutory period.

(ii) **Struck-off Companies:**
The Company has not enetered into the following transactions with the companies struck-off as per Section 248 or Section 560 of the companies act 2013.

(iii) **Benami Property:**
There are no proceeding initiated or pending against the Company as at 31 March 2025, under Benami Property Transactions Act, 1988 (as amended in 2016).

(iv) **Wilful Defaulter:**
The Company is not declared a wilful defaulter by any bank or financial Institution or other lender.

(v) **Undisclosed incomes:**
The Company has recorded all transactions in the books of account that has been surrendered. There are no previously unrecorded incomes and related assets that were considered during the year, no unrecorded incomes were identified as income for tax assessments.

(vi) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(vii) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

(viii) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(ix) The Company has borrowings from banks on the basis of security of current assets. Quarterly returns or statements of current assets filed by the Company with banks are in agreement with the books of accounts.

(x) The Company has used the borrowings from banks for the specific purpose for which it was obtained.

(xi) The Company has not revalued any of its property, plant and equipment (including right-of-use-assets) and intangible assets during the year.

(xii) The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

(xiii) The figures for the corresponding previous year have been regrouped/reclassified wherever necessary to make them comparable.
The notes referred to above form an integral part of these financial statements.

35 Subsequent events:
There are no events subsequent to 31 March 2024 warranting adjustments or disclosures to these financial statements.

The notes referred to above form an integral part of these financial statements.

For M/s Agarwal and Ladda
Chartered Accountants
ICAI Firm Registration No.: 012510S

Deepak Ladda
Partner
Membership No. 223832

AGARWAL & LADDA
HYDERABAD
Chartered Accountants

Place: Hyderabad
Date: 28 July 2026

for and on behalf of the Board of Directors of
Aragen Biologics Private Limited
CIN: U21001TS2023PTC174243

Manmahesh Kantipudi
Director
DIN: 05241166
Place: Hyderabad
Date: 28 July 2026

Keshav Gunupati Venkat Reddy
Director
DIN: 06593325
Place: Hyderabad
Date: 28 July 2026

Sachin Anand Dharap
Chief Financial Officer
Place: Hyderabad
Date: 28 July 2026

Ramakrishna Kasturi
Company Secretary
M.No.: F3865
Place: Hyderabad
Date: 28 July 2026